Although Lilly has shared the topline results of the SURMOUNT-1 trial, now, the full data from the three-year study have been published in the New England Journal of Medicine. The company also recently presented the data at ObesityWeek in San Antonio. The biggest conclusion was that 98.7% (752 of 762) of participants who received tirzepatide…
Lilly’s tirzepatide cuts diabetes risk by 94% in those facing obesity
Eli Lilly’s hit drug tirzepatide has demonstrated a 94% reduction in the risk of developing type 2 diabetes among overweight and obese prediabetic adults, according to new findings from a 176-week Phase 3 trial. The SURMOUNT-1 study, the longest completed trial of tirzepatide to date, also showed sustained weight loss through the treatment period, with…